San Diego, CANCT07866066Now EnrollingIRB Ready

Diabetes Mellitus, Type 2 Clinical Trial in San Diego, CA

Access cutting-edge diabetes mellitus, type 2 treatment through this phase 3 clinical trial at a research site in San Diego. Study-provided care at no cost to qualified participants.

Sponsored by Amgen

Quick Self-Assessment

See if you qualify for this San Diego location

Preparing your pre-screening questions…

Expert Care in San Diego

Access diabetes mellitus, type 2 specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related diabetes mellitus, type 2 treatment provided free

Apply for This San Diego Location

Check if you qualify for this diabetes mellitus, type 2 clinical trial in San Diego, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Diego

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Diego site if eligible
  4. 4Begin participation

About This Diabetes Mellitus, Type 2 Study in San Diego

The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

HbA1c of ≥ 7.5% (58.0 millimoles per mole (mmol/mol)) and ≤ 10.5% (91.0 mmol/mol) at screening.
Treatment of Type 2 diabetes (T2D) with metformin (≥ 1500 milligrams per day (mg/day), or maximum tolerated dose as per investigator judgment) with or without an sodium-glucose cotransporter-2 (SGLT-2) inhibitor on a stable total daily dose for at least 90 days prior to randomization.
Body mass index (BMI) ≥ 25 kilograms per meter squared (kg/m\^2) at screening.

Exclusion Criteria

Type 1 diabetes mellitus (T1DM), history of ketoacidosis or hyperosmolar state/coma, or any other type of diabetes mellitus except T2D or past history of gestational diabetes.
Participants who are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
Participants who have a diagnosis of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy.
One or more episode of severe hypoglycemia (Level 3 hypoglycemia) within 180 days before screening, as defined by the occurrence of neuroglycopenic symptoms requiring the assistance of another person for recovery.
History of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.
Self-reported change in body weight \> 5% within 90 days before screening. Participants must also agree to not initiate an intensive diet or exercise program during the trial with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
Previous or planned (during the trial) surgical, endoscopic, or device-based treatment for obesity. The following are allowed:
liposuction and/or abdominoplasty that was performed \> 1 year before screening.
laparoscopic adjustable gastric banding, intragastric balloon, and/or duodenal-jejunal bypass liner or gastric sleeve if removed \> 1 year before screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Diego?

Yes, this clinical trial (NCT07866066) has an active research site in San Diego, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diabetes Mellitus, Type 2 Treatment Options in San Diego, CA

If you're searching for diabetes mellitus, type 2 treatment options in San Diego, CA, this clinical trial (NCT07866066) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Diego research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced diabetes mellitus, type 2 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diabetes mellitus, type 2 clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in San Diego, CA

See all pulmonary embolism clinical trials recruiting in San Diego — not just this study.

Browse Pulmonary Embolism Trials in San Diego →

Browse More Trials by Condition

Pulmonary Embolism TrialsEssential Tremor TrialsType 2 Diabetes TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in San Diego?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Diego, CA